Form 4: Neuphoria Therapeutics Director Jane Ryan Reports Acquisition and Disposal of Restricted Stock Units

Director Jane Ryan reports transactions involving restricted stock units of Neuphoria Therapeutics Inc.

Summary

• On April 16, 2025, Jane Ryan, a director of Neuphoria Therapeutics Inc., reported acquiring 6,783 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of common stock.
• Ryan also reported disposing of 7,013 derivative securities.
• Following these transactions, Ryan beneficially owns 7,013 derivative securities.
• The RSUs will fully vest on the day prior to the company's next annual shareholder meeting, expected no later than November 30, 2025, contingent upon continuous service to the company.

Sentiment

Score: 5

Explanation: This is a neutral report of stock transactions by a company director. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Future Outlook

The RSUs will fully vest on the day prior to the company's next annual shareholder meeting, expected no later than November 30, 2025, contingent upon continuous service to the company.

Industry Context

This is a standard SEC Form 4 filing, reflecting changes in beneficial ownership by a company insider. It's a routine part of corporate governance and provides transparency to the market regarding insider transactions.

Stakeholder Impact

• The filing provides transparency to shareholders regarding insider transactions, which can influence investor confidence.

Key Dates

Keywords

Form 4, Beneficial Ownership, Restricted Stock Units, NEUP, Neuphoria Therapeutics, Director, Jane Ryan